WELL HEALTH TECHNOLOGIES COR (WELL.CA) Fundamental Analysis & Valuation
TSX:WELL • CA94947L1022
Current stock price
4.3 CAD
+0.15 (+3.61%)
Last:
This WELL.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. WELL.CA Profitability Analysis
1.1 Basic Checks
- In the past year WELL was profitable.
- WELL had a positive operating cash flow in the past year.
- In multiple years WELL reported negative net income over the last 5 years.
- WELL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -0.35%, WELL perfoms like the industry average, outperforming 53.85% of the companies in the same industry.
- WELL has a better Return On Equity (-0.85%) than 61.54% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 4.48%, WELL is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.35% | ||
| ROE | -0.85% | ||
| ROIC | 4.48% |
ROA(3y)0.49%
ROA(5y)-0.37%
ROE(3y)0.97%
ROE(5y)-0.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- WELL has a better Operating Margin (6.62%) than 69.23% of its industry peers.
- In the last couple of years the Operating Margin of WELL has grown nicely.
- WELL has a better Gross Margin (44.20%) than 69.23% of its industry peers.
- WELL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.62% | ||
| PM (TTM) | N/A | ||
| GM | 44.2% |
OM growth 3Y16.22%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.05%
GM growth 5Y0.91%
2. WELL.CA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), WELL is destroying value.
- The number of shares outstanding for WELL has been increased compared to 1 year ago.
- Compared to 5 years ago, WELL has more shares outstanding
- Compared to 1 year ago, WELL has a worse debt to assets ratio.
2.2 Solvency
- WELL has an Altman-Z score of 1.35. This is a bad value and indicates that WELL is not financially healthy and even has some risk of bankruptcy.
- WELL has a Altman-Z score of 1.35. This is comparable to the rest of the industry: WELL outperforms 53.85% of its industry peers.
- WELL has a debt to FCF ratio of 7.56. This is a slightly negative value and a sign of low solvency as WELL would need 7.56 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 7.56, WELL is doing good in the industry, outperforming 61.54% of the companies in the same industry.
- A Debt/Equity ratio of 0.70 indicates that WELL is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.70, WELL is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 7.56 | ||
| Altman-Z | 1.35 |
ROIC/WACC0.55
WACC8.09%
2.3 Liquidity
- A Current Ratio of 1.03 indicates that WELL should not have too much problems paying its short term obligations.
- WELL has a Current ratio of 1.03. This is in the better half of the industry: WELL outperforms 76.92% of its industry peers.
- WELL has a Quick Ratio of 1.03. This is a normal value and indicates that WELL is financially healthy and should not expect problems in meeting its short term obligations.
- WELL has a Quick ratio of 1.03. This is in the better half of the industry: WELL outperforms 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 |
3. WELL.CA Growth Analysis
3.1 Past
- The earnings per share for WELL have decreased strongly by -26.67% in the last year.
- Looking at the last year, WELL shows a very strong growth in Revenue. The Revenue has grown by 52.25%.
- Measured over the past years, WELL shows a very strong growth in Revenue. The Revenue has been growing by 94.58% on average per year.
EPS 1Y (TTM)-26.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%766.67%
Revenue 1Y (TTM)52.25%
Revenue growth 3Y35%
Revenue growth 5Y94.58%
Sales Q2Q%63.9%
3.2 Future
- The Earnings Per Share is expected to grow by 40.64% on average over the next years. This is a very strong growth
- WELL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.14% yearly.
EPS Next Y172%
EPS Next 2Y89.9%
EPS Next 3Y40.64%
EPS Next 5YN/A
Revenue Next Year11.69%
Revenue Next 2Y9.2%
Revenue Next 3Y8.14%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. WELL.CA Valuation Analysis
4.1 Price/Earnings Ratio
- WELL is valuated quite expensively with a Price/Earnings ratio of 39.09.
- WELL's Price/Earnings ratio is a bit cheaper when compared to the industry. WELL is cheaper than 69.23% of the companies in the same industry.
- When comparing the Price/Earnings ratio of WELL to the average of the S&P500 Index (27.42), we can say WELL is valued slightly more expensively.
- With a Price/Forward Earnings ratio of 14.37, WELL is valued correctly.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of WELL indicates a rather cheap valuation: WELL is cheaper than 84.62% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.29. WELL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.09 | ||
| Fwd PE | 14.37 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, WELL is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
- 69.23% of the companies in the same industry are more expensive than WELL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.69 | ||
| EV/EBITDA | 8.99 |
4.3 Compensation for Growth
- WELL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- WELL's earnings are expected to grow with 40.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y89.9%
EPS Next 3Y40.64%
5. WELL.CA Dividend Analysis
5.1 Amount
- No dividends for WELL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
WELL.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:WELL (4/24/2026, 7:00:00 PM)
4.3
+0.15 (+3.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-19 2026-03-19/bmo
Earnings (Next)05-13 2026-05-13
Inst Owners3.71%
Inst Owner ChangeN/A
Ins Owners22.55%
Ins Owner ChangeN/A
Market Cap1.10B
Revenue(TTM)1.40B
Net Income(TTM)-7.36M
Analysts82
Price Target7.21 (67.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.38%
Min EPS beat(2)-32.99%
Max EPS beat(2)87.74%
EPS beat(4)1
Avg EPS beat(4)-170.63%
Min EPS beat(4)-696.08%
Max EPS beat(4)87.74%
EPS beat(8)3
Avg EPS beat(8)2157.64%
EPS beat(12)3
Avg EPS beat(12)1034.47%
EPS beat(16)4
Avg EPS beat(16)745.25%
Revenue beat(2)0
Avg Revenue beat(2)-2.78%
Min Revenue beat(2)-3.29%
Max Revenue beat(2)-2.26%
Revenue beat(4)1
Avg Revenue beat(4)-1.3%
Min Revenue beat(4)-3.29%
Max Revenue beat(4)1.59%
Revenue beat(8)2
Avg Revenue beat(8)-2.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.86%
Revenue beat(16)8
Avg Revenue beat(16)0%
PT rev (1m)-7.38%
PT rev (3m)-7.61%
EPS NQ rev (1m)-8.16%
EPS NQ rev (3m)-27.42%
EPS NY rev (1m)-29.32%
EPS NY rev (3m)-28.28%
Revenue NQ rev (1m)-0.4%
Revenue NQ rev (3m)-1.05%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.09 | ||
| Fwd PE | 14.37 | ||
| P/S | 0.78 | ||
| P/FCF | 11.69 | ||
| P/OCF | 9.01 | ||
| P/B | 1.27 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.99 |
EPS(TTM)0.11
EY2.56%
EPS(NY)0.3
Fwd EY6.96%
FCF(TTM)0.37
FCFY8.56%
OCF(TTM)0.48
OCFY11.09%
SpS5.48
BVpS3.38
TBVpS-2.68
PEG (NY)0.23
PEG (5Y)N/A
Graham Number2.89212 (-32.74%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.35% | ||
| ROE | -0.85% | ||
| ROCE | 5.33% | ||
| ROIC | 4.48% | ||
| ROICexc | 4.85% | ||
| ROICexgc | 134.73% | ||
| OM | 6.62% | ||
| PM (TTM) | N/A | ||
| GM | 44.2% | ||
| FCFM | 6.71% |
ROA(3y)0.49%
ROA(5y)-0.37%
ROE(3y)0.97%
ROE(5y)-0.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y61.44%
ROICexgc growth 5YN/A
ROICexc growth 3Y39.71%
ROICexc growth 5YN/A
OM growth 3Y16.22%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.05%
GM growth 5Y0.91%
F-Score5
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 7.56 | ||
| Debt/EBITDA | 3.22 | ||
| Cap/Depr | 29.72% | ||
| Cap/Sales | 1.99% | ||
| Interest Coverage | 3 | ||
| Cash Conversion | 65.37% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | 1.35 |
F-Score5
WACC8.09%
ROIC/WACC0.55
Cap/Depr(3y)21.84%
Cap/Depr(5y)16.82%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%766.67%
EPS Next Y172%
EPS Next 2Y89.9%
EPS Next 3Y40.64%
EPS Next 5YN/A
Revenue 1Y (TTM)52.25%
Revenue growth 3Y35%
Revenue growth 5Y94.58%
Sales Q2Q%63.9%
Revenue Next Year11.69%
Revenue Next 2Y9.2%
Revenue Next 3Y8.14%
Revenue Next 5YN/A
EBIT growth 1Y401.33%
EBIT growth 3Y56.9%
EBIT growth 5YN/A
EBIT Next Year111.26%
EBIT Next 3Y39.56%
EBIT Next 5YN/A
FCF growth 1Y1666.71%
FCF growth 3Y10.25%
FCF growth 5YN/A
OCF growth 1Y1092.06%
OCF growth 3Y16.77%
OCF growth 5YN/A
WELL HEALTH TECHNOLOGIES COR / WELL.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of WELL HEALTH TECHNOLOGIES COR (WELL.CA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to WELL.CA.
Can you provide the valuation status for WELL HEALTH TECHNOLOGIES COR?
ChartMill assigns a valuation rating of 6 / 10 to WELL HEALTH TECHNOLOGIES COR (WELL.CA). This can be considered as Fairly Valued.
How profitable is WELL HEALTH TECHNOLOGIES COR (WELL.CA) stock?
WELL HEALTH TECHNOLOGIES COR (WELL.CA) has a profitability rating of 5 / 10.
What is the financial health of WELL HEALTH TECHNOLOGIES COR (WELL.CA) stock?
The financial health rating of WELL HEALTH TECHNOLOGIES COR (WELL.CA) is 4 / 10.